# Esperion to be Acquired by ARCHIMED
Canonical URL: https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed
Ticker: ESPR
Company: Esperion Therapeutics
Source: Esperion Therapeutics
Published: 2026-05-01 11:00 EST
Original Source URL: https://www.esperion.com
## Summary

Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 01, 2026 (GLOBE NEWSWIRE) -- Esperion

## Article Body
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 01, 2026 (GLOBE NEWSWIRE) -- Esperion
## Recent Company News
- 2026-05-26 12:00 EST — [Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study-at-the-european-atherosclerosis-society-congress-2026) — Source: Esperion Therapeutics
- 2026-05-14 20:30 EST — [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Esperion Therapeutics
- 2026-05-13 12:00 EST — [Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-announces-two-new-analyses-supporting-bempedoic-acid-to-reduce-ldl-c-levels-to-be-presented-at-the-european-atherosclerosis-society-eas-congress-2026) — Source: Esperion Therapeutics
- 2026-05-01 11:00 EST — [Esperion to be Acquired by ARCHIMED](https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed) — Source: Esperion Therapeutics
- 2026-04-23 12:00 EST — [Esperion to Report First Quarter 2026 Financial Results on May 7](https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7) — Source: Esperion Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)